Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4638141 | 0.88 | L3MBTL1 (0.54) | CCR8KDM4EALDH1A1GRIN2BSMN1; SMN2 | |
| SCHEMBL4638143 | 0.88 | L3MBTL1 (0.54) | CCR8KDM4EALDH1A1GRIN2BSMN1; SMN2 | |
| SCHEMBL2904781 | 0.88 | L3MBTL1 (0.54) | CCR8KDM4EALDH1A1GRIN2BSMN1; SMN2 | |
| SCHEMBL17048459 | 0.87 | KDM4E (0.62) | CCR8KDM4EALDH1A1HPGDHTT | |
| SCHEMBL17108223 | 0.86 | CCR8 (0.68) | CCR8KDM4EALDH1A1HPGDHTT | |
| SCHEMBL17099348 | 0.82 | KDM4E (0.64) | CCR8KDM4EALDH1A1HPGDHTT | |
| SCHEMBL17055902 | 0.81 | GRIN2B (0.56) | CCR8KDM4EALDH1A1HPGDHTT | |
| SCHEMBL6529627 | 0.80 | CCR8 (0.77) | CCR8MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL12696580 | 0.77 | GRIN2B (0.54) | GRIN2BDRD4 | |
| SCHEMBL2069105 | 0.77 | GRIN2B (0.54) | GRIN2BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-13 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-08-17 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9676757-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-3110794-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2017-01-04 | — | — | EP | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| WO-2015130905-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130905-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233377-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | CCR8 3573/4885MEN1 2625/4885KMT2A 2908/4885 |
| US-20150266862-A1 | HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF | CACNA1B, CACNG6, SCN5A | CCR8 3573/4885MEN1 2625/4885KMT2A 2908/4885 |
| US-10377745-B2 | Heterocyclic compounds as NaV channel inhibitors and uses thereof | CACNA1B, CACNG6, SCN5A | CCR8 3573/4885MEN1 2625/4885KMT2A 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.